Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1717)	5/27/1998 11:06:00 AM
From: Ranger	Read Replies (1) \| Respond to of 1894

Recieved that e-mail also.Opinion?

To: Sigmund who wrote (1717)	5/27/1998 11:28:00 AM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Sigmund, <<"Oncometrics has recently completed a multi-national early lung cancer screening field study involving more than a thousand samples demonstrating the feasibility of the routine clinical use of quantitative microscopy techniques to nearly double the detection rate of early stage, curable lung cancer cases... A doubling of detection rates of early stage curable lung cancer should be rapidly accepted by clinical diagnostic labs and medical insurance providers. Currently, pulmonary cancer patients undergo very costly treatments. I have heard figures totalling several hundred thousand dollars per patient and because the current detection methodology detects at such a late stage in the cancer development... the patients ultimately perish after the expensive and somewhat futile attempt at treatment. I have lost a few friends and relatives and know one "relation of a relation" who has been lingering for quite some time. An earlier stage detection system could save lives and insurance dollars. If the claim of the doubling of the detection rate at an early stage is accurate.... medical providers will insist that this form of detection be used as opposed to the current practices. It does not sound like this is a case where current methodologies are written in stone as seems to be the case with the 50 year old PAP smear. A friend of mine Emailed me saying there was a piece on the news last night stating that Automatic PAP screening tests aren't cost justified. I don't think this dispute will carry over into the Savant area of cyto-metric evaluation if the doubling of the detection rate claims are valid. I would eventually expect AccuMed to eventually comment regarding some involvement with a company called; Cell Analysis Systems, Inc. of N.J.; which has some years of expertise in this area. It is my understanding that Dr. Pressman of AccuMed is on first name terms with the principals of Cell Analysis Systems.... and Cell Analysis Systems, Inc. have referenced Dr. Pressman's research thesis in their own work. AccuMed may have been a late entrant into the cervical screening realm... let's see what they can do with this. Let's see what the medical profession thinks about the AcCell/Savant. I think this is what Sakura is interested in marketing and why they have waited silently in the wings and have taken a position in AccuMed. Perhaps we will find out shortly. Bellingham evidently also realizes the market potential for this device and would explain their involvement with AccuMed. Too bad the news story regarding the Savant has not shown up on the news wires.... more problems stemming from the temporary suffix symbol changes no doubt.